University of Virginia Patent Foundation

Hoechst Roussel Pharmaceuticals

Other

Wisconsin Alumni Research Foundation

Adenosine Therapeutics, LLC

Gail W Sullivan

Joel M Linden

Timothy L MacDonald

Jayson Michael Rieger

Robert Alan Figler

Lauren J Murphree

William J Novick, Jr

Gerald L Mandell

Ian J Sarembock

Robert Douglas Thompson

Mark D Okusa

W Michael Scheld

Irving L Kron

Kenneth Brayman

Donald L Kimpel

W Michael Sheld

Lauren Murphree Mihalcik

The invention provides compounds having the following general formula (I): 

2-propynyl adenosine analogs having A2A agonist activity and compositions thereof

2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity

2-polycyclic propynyl adenosine analogs having A2A agonist activity

The invention provides compounds having the following general formula (I): wherein X, R, R, Rand Z are as described herein.

[object Object]

The present invention provides a therapeutic method for treating biological diseases that includes the administration of an effective amount of a suitable antibiotic agent, antifungal agent or antiviral agent in conjunction with an Aadenosine receptor agonist. If no anti-pathogenic agent is known the Aagonist can be used alone to reduce inflammation, as may occur during infection with antibiotic resistant bacteria, or certain viruses such as those that cause SARS or Ebola. Optionally, the method includes administration of a type IV PDE inhibitor.

Method to reduce inflammatory response in transplanted tissue

The present invention provides a therapeutic method for treating an inflammatory response caused by autoimmune stimulation, comprising the administration to a patient in need thereof of an antiinflammatory amount amount of an Aadenosine receptor agonist. The autoimmune stimulation can be caused by arthritis, particularly rheumatoid arthritis. Optionally, the method includes administration of a type IV PDE inhibitor.

Method to reduce an inflammatory response from arthritis

The present invention provides compositions for oral administration of compounds having Aadenosine receptor agonist activity. These compositions are useful for treatment of inflammatory conditions.

The invention provides compounds having the following general formula (I): wherein X, R, R, Rand Z are as described here.

Agonists of A adenosine receptors optionally, in combination with a Type IV phosphodiesterase (PDE) inhibitor are effective for the inhibition of an inflammatory response in mammalian tissue, in vivo or in vitro.

Method and compositions for treating the inflammatory response

Compounds and methods are provided to treat inflammatory conditions with certain A adenosine receptor antagonists.

Methods and compositions for treating inflammatory response

Agonists of A adenosine receptors optionally, in combination with a Type IV phosphodiesterase (PDE) inhibitor are effective for the treatment of the inflammatory response of mammalian tissue.

Method compositions for treating the inflammatory response

Agonists of A adenosine receptors in combination with rolipram, its derivatives or other Type IV phosphodiesterase (PDE) inhibitors are effective for the treatment of restenosis.

Growing community of inventors

Charlottesville, VA, United States of America

Gail W Sullivan